Chronic lymphocytic leukaemia (CLL) is associated with apoptosis resistance and defective control of cell growth. Our study describes for the first time a critical role in CLL for the KRAB-zinc finger protein ZNF224. High ZNF224 transcript levels were detected in CLL patients with respect to control cells. Moreover, ZNF224 expression was significantly lowered after conventional chemotherapy treatment in a subset of CLL patients. By in vitro experiments we confirmed that ZNF224 expression is suppressed by fludarabine and demonstrated that ZNF224 is involved in apoptosis resistance in CLL cells. Moreover, we showed that ZNF224 positively modulates cyclin D3 gene expression. Consistently, we observed that alteration of ZNF224 expression leads to defects in cell cycle control. All together, our results strongly suggest that in CLL cells high expression level of ZNF224 can lead to inappropriate cell growth and apoptosis resistance, thus contributing to CLL progression. Targeting ZNF224 could thus improve CLL response to therapy.
Introduction
Chronic lymphocytic leukaemia (B-CLL) is a B-cell malignant disorder caused by defects in apoptosis and prolonged survival in vivo of CLL cells (1, 2) . Despite significant progress in the treatment modalities, CLL remains incurable and drug resistance is a major cause of treatment failure (3, 4) . Therefore, a better understanding of the molecular mechanisms leading to growth advantage and resistance to chemotherapy in leukemic cells is required.
In this study, we propose a role for the KRAB-zinc finger transcription factor, ZNF224, in cell growth and chemoresistance of CLL cells. ZNF224, as other repressors containing the KRAB domain, inhibits the transcription of its target genes through the interaction with co-repressor KAP1, which in turn recruits chromatin modifying activities (5) . Also, the ZNF224-mediated transcriptional repression requires the methylation of arginine 3 of histone H4 by PRMT5, a type II protein arginine methyltransferase (6) . Moreover, our recent findings indicate that ZNF224 can also function as a transcriptional co-factor of the Wilms' tumour protein 1, WT1, in the transcriptional regulation of WT1 target genes (7) . ZNF224/WT1 interaction plays a significant role in the regulation of apoptotic events in chronic myelogenous leukaemia (CML) cells (8) (9) (10) .
The cancer testis antigen DEPDC1 has been identified as a novel molecular partner of ZNF224. ZNF224/DEPDC1 complex is involved in bladder carcinogenesis by repressing the transcription of A20 gene, an inhibitor of the NF-kB pathway (11) .
More recently, it has been demonstrated that ZNF224 induces cell growth and apoptosis resistance in breast cancer by increasing miR-663a transcription (12) .
These studies indicate a role for ZNF224 in carcinogenesis and suggest that it behaves as a tumor suppressor or an oncogene depending on cellular contest and interacting protein complexes.
The dual role of ZNF224 is confirmed by the results herein described, showing that, differently from what we had previously demonstrated in CML, ZNF224 plays an important oncogenic role in CLL. Indeed, we observed that ZNF224 is overexpressed in CLL patients and downmodulated following chemotherapy treatment. In vitro experiments, conducted in leukaemia cell lines, either resistant or responsive to fludarabine, demonstrated that ZNF224 expression is associated with survival advantages and drug-resistance. Furthermore, we demonstrated that ZNF224 positively modulates cyclin D3 gene expression, thus likely contributing, besides apoptosis resistance, also to impaired growth of CLL cells.
Results

ZNF224 expression in CLL patients
To investigate the implication of ZNF224 in CLL development, we evaluated the expression levels of ZNF224 mRNA in B-CLL specimens from 60 patients. Patients were either at diagnosis or untreated for at least one year before the study. Interestingly, the cells obtained from patient samples exhibited higher ZNF224 transcript levels than lymphocytes from healthy donors (P < 0,001) (Fig. 1A) . We also evaluated the mRNA expression of cyclin D3 (CCND3), a key cell cycle regulatory component with oncogenic potential (13) , whose expression is altered in CLL (14) . CLL patients also showed CCND3 mRNA levels significantly higher than healthy donors (P < 0,001) (Fig. 1A) . We next analysed the expression level of ZNF224 in CLL cells of 10 patients at diagnosis and after the second cycle of fludarabine treatment or fludarabine combination therapies. We observed that ZNF224 was downmodulated after treatments in 8 out of 10 patients (P ¼ 0.027) (Fig. 1B) . Interestingly, the two patients with increased expression of ZNF224 following chemotherapy were refractory to treatment and developed disease progression, allowing us to hypothesize that ZNF224 could influence the response to fludarabine therapy.
Furthermore, we observed a moderate but significant positive correlation between ZNF224 and both the absolute lymphocyte count (%ALC) (Pearson r ¼ 0.29, P ¼ 0.026) and CCND3 expression (Pearson r ¼ 0.29, P ¼ 0.026) (Fig. 1C and D) .
These findings prompted us to hypothesize that the high levels of ZNF224 expression in B-CLL patients could play a pathogenic role in B-cell malignancies.
Fludarabine modulates ZNF224 expression at transcriptional level in leukaemia cells
To investigate whether ZNF224 was involved in the response to fludarabine we used Jurkat cells, a cell line fludarabine-sensitive derived from an acute T cell leukaemia and MEC1, a cell line fludarabine-resistant derived from B-cell chronic lymphocytic leukaemia. At first, we observed that ZNF224 expression levels are sensibly lower in Jurkat than in MEC1 cells (Supplementary Material, Fig. S1 ).
Successively, Jurkat cells were treated with 3 mM fludarabine for 1 h, 3 h, 6 h, 12 h, 24 h, 48 h, after which annexin assay was performed to evaluate apoptosis and ZNF224 expression level was measured by real time-PCR analysis (RTqPCR). We observed that annexin binding was induced by fludarabine in a timedependent manner ( Fig. 2A) . Interestingly, a rapid and strong downregulation of ZNF224 mRNA and protein levels after fludarabine treatment was associated with a rapid apoptotic response ( Fig. 2B and C) .On the contrary, in MEC1 cells the apoptotic effects were only observed at higher concentration (50 mM) and longer duration of fludarabine treatment (72 h) (Fig. 2D) . Furthermore, a different modulation of ZNF224 expression was observed in resistant MEC1 cells. Indeed, we observed that after an initial decrease (1-12 h), the ZNF224 mRNA level was increased by 24 h and 48 h treatment with fludarabine. The expression of ZNF224 began to decrease again at both mRNA These results suggest that, similarly to other factors associated with drug resistance (15) , the initial induction of ZNF224 expression may be related to the MEC1 cells ability to resist to the drug treatment; the subsequent decrease of ZNF224 levels could be associated to the activation of cellular mechanisms that sensitize cells to apoptosis.
In addition, we measured the expression levels of Ki-67 mRNA, a proliferation marker commonly used to detect proliferating cells (16) , in Jurkat and MEC1 cells following fludarabine treatment ( Fig. 2B and E ). This analysis revealed that ZNF224 and Ki-67 transcripts showed a similar modulation in Jurkat but not in MEC1 cells. In fact, in MEC1 cells, an opposite trend was observed for Ki67 mRNA compared to that of ZNF224 at 72 h treatment (Fig. 2E ). This may be due to the presence of MEC1 fludarabine-resistant cells that are able to escape killing and thus continue to proliferate.
We next examined whether ZNF224 is transcriptionally downmodulated by fludarabine. To this aim, we used a reporter plasmid (PromZNF224-LUC) containing the human ZNF224 promoter cloned upstream of the Firefly Luciferase Gene. The Jurkat and MEC1 cells were transfected with PromZNF224-LUC and 24 h after transfection were treated with 3 lM and 50 lM fludarabine, respectively, for 24 and 48 h. As shown in Fig. 3 , the fludarabine treatment caused a strong time-dependent reduction of PromZNF224-LUC transcriptional activity in Jurkat cells. Instead, in MEC1 cells the PromZNF224-LUC activity was increased after 24 h fludarabine treatment and decreased only after 48 h treatment.
We thus speculate that the initial rise of the ZNF224 promoter activity may be related to molecular mechanisms of MEC1 resistance to drug treatment.
ZNF224 expression affects the apoptotic response to fludarabine treatment
Our data show that downmodulation of ZNF224 is associated with fludarabine-induced apoptosis in both Jurkat sensitive and MEC1 resistant CLL cells. Moreover, the different expression levels of ZNF224 (Supplementary Material, Fig. S1 ) and the different modulation of its expression by fludarabine in sensitive and resistant leukaemia cells (Figs 2 and 3) led us to suppose that ZNF224 could be involved in drug resistance.
In an attempt to study the role of ZNF224 in the resistant behaviour of CLL cells, we evaluated the apoptotic response to fludarabine in pools of MEC1 cells stably silenced for ZNF224 (MEC1.C3 and MEC1.E7 clones). These cells and their corresponding control (MEC1.GFP clone) were cultured with or without 50 mM fludarabine for 24 h, 48 h and 72 h and then apoptosis was analysed by FACS. We observed that ZNF224 silencing makes MEC1 cells significantly more susceptible to fludarabine induced apoptosis, already at 24 h treatment (Fig. 4A ). This result indicates that ZNF224 expression is associated with survival advantages and resistance to fludarabine treatment of MEC1 cells.
The ZNF224 effects on apoptotic response to fludarabine were also assessed in fludarabine sensitive Jurkat cells overexpressing ZNF224. To this aim, Jurkat cells were infected with two different lentiviral expression vectors for 3xFlag-ZNF224, PHIV-ZNF224.4 and PHIV-ZNF224.8, respectively, and the control vector PHIV-EGFP. The overexpression of Flag-ZNF224 in infected Jurkat cells was verified by western blot analysis (Fig. 4B , right panel). Jurkat cells overexpressing Flag-ZNF224 and the negative control were treated with fludarabine at 3 mM or 9 mM for 24 h, 48 h and 72 h. Subsequently, apoptosis was examined by Annexin V assay. Our results showed that the ZNF224 overexpression makes the Jurkat cells more resistant to fludarabineinduced apoptosis. Indeed, following treatment with fludarabine, there was a significant decrease in the number of apoptotic cells in PHIV-ZNF224.4 and PHIV-ZNF224. 8 Jurkat cells compared to control cells (Fig. 4B, left panel) .
Cyclin D3 is a new target gene of ZNF224
We had previously observed a positive correlation between ZNF224 and CCND3 expression levels in CLL patients and an association of fludarabine-mediated suppression of ZNF224 with apoptosis induction in leukaemia cells. CCND3 is involved in regulation of apoptosis and in the resistant behaviour of CLL cells (15) . Therefore, we speculated that ZNF224 could affect fludarabine sensitivity of CLL cells as a result of the modulation of proteins that normally have a key role in cell cycle progression, such as CCND3, and that it could suppress the apoptosis in an anti-proliferative cellular context (17) .
In order to evaluate the impact of ZNF224 on CCND3 expression, MC3 cells (Epstein-Barr virus immortalized B-cells) were silenced for ZNF224 by RNAi. ZNF224 and CCDN3 protein expression was evaluated by western blot analysis. As shown in Fig. 5A , ZNF224 knockdown resulted in downregulation of CCDN3 expression. Considering that CCND3 suppression induces apoptosis, we asked whether ZNF224-dependent CCDN3 downmodulation affects apoptosis. As shown in Fig. 5B , an apoptosis assay revealed that ZNF224 silencing was associated with a strongly increased apoptosis rate in MC3 cells compared to control cells (NS).
Subsequently, we conducted an in silico analysis of putative binding motifs for ZNF224 (18) located in the CCND3 gene. We found putative binding sites for ZNF224 in the regulative region upstream the transcription start site and in an intronic sequence of CCND3 gene. Thus, we evaluated whether ZNF224 could directly bind the CCND3 gene. To this aim, cross-linked chromatin was prepared from pools of PBMCs derived from healthy donors that were induced to proliferate in vitro by antiIgM stimulation. The DNA/protein complexes were immunoprecipitated with a specific antibody for endogenous ZNF224 protein and immunoglobulin G as previously described (6) . Immunoprecipitated DNA was PCR-amplified with CCND3 specific primers covering two different promoter regions (p1 and p2), and two different regions of the second intron (int1 and int2) (Fig. 6A ). As shown in Fig. 6B , ZNF224 binds to the CCND3 promoter (p1 region) and to an intronic region (int1) in activated PBMCs. Furthermore, the histone modifications, associated with an active or inactive transcriptional state, were examined at p1, p2, int1 and int2 regions of CCND3 gene performing ChIP experiments with trimethylated H3K27 antibody (H3K27me3) and trimethylated H3K4 antibody (H3K4me3) (Fig. 6C) . The high level of H3K4me3, marker of active transcriptional state, compared to H3K27me3 at p2 and int1 DNA regions strongly supports a role for ZNF224 in transcriptional activation of CCND3 gene.
All together, these results indicate that ZNF224 is a positive regulator of CCND3 gene expression.
ZNF224 plays a role in cell cycle progression
The above mentioned results indicate the involvement of ZNF224 in cell cycle modulation, through the transcriptional regulation of CCND3.
To investigate the functional implications of ZNF224 on cell cycle progression, we performed a flow cytometry cell cycle analysis in MEC1 cells stably silenced for ZNF224. The FACSbased cell cycle analysis revealed that the knock-down of ZNF224 led to a decreased number of cells in G2/M phase and to the accumulation of cells in the G0/G1 phase of the cell cycle. A less marked change was observed in S cell population in either cell groups with respect to control (Fig. 7A) .
Consistent with the cell cycle profile, we observed that the expression of Ki67 and cyclin B1, both varying through the cell cycle with their peak in G2/M, was decreased in ZNF224 silenced MEC1 cells. In addition, we observed low levels of cyclin D3 and high expression levels of cyclin A (Supplementary Material, Fig. S2 ).
To support these data, we investigated whether the effects on cell cycle were reversed by ZNF224 overexpression. To this aim, we infected MEC1.C3 and MEC1.E7 clones, stably knockeddown for ZNF224, with PHIV-ZNF224.4 and PHIV-ZNF224.8 expression vectors for ZNF224 and control vector PHIV-EGFP. As shown in Fig. 7B and C, we observed that ZNF224 expression, recovered through PHIV-ZNF224 infection, increased the number of cells in S and G2/M phase.
Taken together, these findings provide evidence that ZNF224 plays a role in the cell cycle progression and could control the entry into and the exit from S and G2/M phases.
Discussion
Chronic lymphocytic leukaemia (B-CLL) is characterized by the accumulation in vivo of clonal lymphocytes that show prolonged survival because of inhibition of apoptosis and alterations of genes involved in cell cycle control (19, 20) .
Although the majority of CLL cells are arrested in the G0/G1 phase of the cell cycle, recent findings indicate that most CLL clones comprise activated cells displaying activation associated-markers (21) . In addition, the signals that enable CLL cell to survive and proliferate arise from specific microenvironmental structures such as lymph nodes and bone marrow (19) . Consequently, the elucidation of the molecular mechanisms and the identification of factors that control cell cycle and apoptosis could contribute to understand the B-CLL pathophysiology, since imbalance of these processes can lead to growth advantage and resistance to chemotherapy of leukemic cells.
Here, we demonstrate that the over-expression of ZNF224 results in cell survival and suppression of apoptosis of CLL cells. Also, our results strongly suggest that ZNF224 contribute to drug resistance of CLL cells through the deregulation of cell cycle machinery.
We measured ZNF224 mRNA expression levels in CLL cells from 60 patients, revealing high levels of ZNF224 expression and a significant positive correlation between ZNF224 and both CCND3 expression and absolute lymphocyte count (%ALC), both of them reported as markers for poor prognosis in leukaemia (22) . In CLL the absolute daily production of lymphocyte and CCND3 expression levels are high compared to healthy subjects and correlate with a low survival rate. Thus, high expression of ZNF224 is consistent with some evidence, suggesting CLL as a dynamic disease (23) . These findings indicate that ZNF224 expression could represent a new negative prognostic factor in CLL patients.
The clinical course of CLL is highly variable and the identification of novel prognostic factors in addition to ZAP-70 and CD38 (24) could contribute to improve the CLL classification.
We searched a correlation between ZNF224 gene expression and patient prognosis in other B-cell malignancies by using two different online databases, PrognoScan (http://www.progno scan.org/) and R2: Genomics Analysis and Visualization Platform (http://r2.amc.nl). Kaplan-Meier plots provided by these datasets showed that in B-cell lymphoma the patient group with high ZNF224 expression had a lower overall survival probability, thus supporting the notion that ZNF224 expression may affect survival time in B-cell malignancies. Moreover, we observed association of high ZNF224 expression with poor survival in some solid and soft tissue cancer such as brain, lung and liposarcoma tumour.
Interestingly, ZNF224 expression levels significantly decreased in 8 out of 10 CLL patients following treatment with chemotherapeutic drugs, while ZNF224 expression increased in two chemotherapy-refractory patients. These data, although based on only a small number of patients, suggest that ZNF224 could be used as a novel biomarker to monitor and predict the clinical response to fludarabine treatment in CLL patients. Analysis of the correlation between ZNF224 expression levels and chemoteraphy responsiveness in a larger cohort of CLL patients is required to assess the potential use of ZNF224 as a useful tool to design therapy and to monitor the clinical outcome in patients undergoing chemotherapy.
Moreover, the observed downmodulation of ZNF224 following pharmacological treatment in CLL patients leads us to speculate that ZNF224 could represent a promising new therapeutic target for the development of innovative therapeutic approaches in CLL. Indeed, despite significant effectiveness showed by new treatment in CLL, some patient relapses and others do not respond to treatment. The use of agents capable to suppress ZNF224 expression in combination with conventional or newer drugs may be exploited as a basis for the development of new therapeutic approach to overcome drug resistance and improve treatment outcome of CLL patients. To this aim, the identification of factors that regulate the expression of ZNF224 in CLL and the understanding of the molecular pathways in which ZNF224 is involved will be required.
In vitro experiments clarified the molecular function of ZNF224 in CLL and strengthened the data obtained in patients. At first, we observed a strong down-regulation of ZNF224 combined with the induction of apoptosis in leukaemia cell lines following fludarabine treatment, even if a delayed ZNF224 repression and, consequently, a delayed apoptotic response was observed in MEC1 resistant cell line with respect to sensitive Jurkat cells. We also demonstrated that overexpression of ZNF224 inhibits fludarabine-induced apoptosis in Jurkat cells, whereas the fludarabine-resistant MEC1 cells become sensitive to the drug treatment following ZNF224 depletion. These data strongly indicate that in vitro sensitivity to fludarabine of CLL cells may be dependent, at least in part, on ZNF224 expression level.
CCND3 is a cell cycle regulators mediating G1/S transition and apoptosis regulation (25, 26) . Overexpression of CCND3 has been described in B-CLL cells (14) and its downmodulation induced cell cycle arrest and apoptosis (27) .
In this study, we demonstrated that the knockdown of ZNF224 is accompanied by downmodulation of CCND3 expression and induction of apoptosis in immortalized B-cells. Furthermore, chromatin immunoprecipitation experiments showed the binding of ZNF224 to CCND3 gene in vivo. These results indicate that CCND3 is a target of ZNF224 transcriptional activation. We also showed that ZNF224 affects cell cycle progression. Indeed, ZNF224 depletion in MEC1 cells induced an increase of resting CLL cells, while the rescue of ZNF224 expression induced a significant cell cycle entry.
This allowed us to speculate that ZNF224 overexpression in B-CLL cells leads to deregulated cell proliferation through an increase of CCND3 transcription, thus preventing CLL cells from cell-cycle arrest and apoptosis. ZNF224 may represent one of the factors that links the unregulated cell proliferation to apoptosis resistance in CLL. However, we cannot rule out that ZNF224 could participate in the transcriptional regulation of other not yet identified target genes, involved in cell cycle progression and apoptosis.
We previously demonstrated a proapoptotic role for ZNF224 in chronic myeloid leukaemia, acting as a transcriptional cofactor of WT1 (8) (9) (10) . Other authors showed that ZNF224 affects cell growth and suppression of apoptosis in bladder and breast cancer cells (11, 12) . These data highlight a dual role for ZNF224 in cancer. The interaction with different cofactors and the ability of ZNF224 itself to act as a transcriptional cofactor may govern the ZNF224-mediated transcriptional regulation of gene expression. The characterization in different cell types of the multiprotein transcriptional complexes which ZNF224 is involved in will contribute to elucidate how alterations of these complexes could affect apoptosis and cell growth in cancer.
Materials and Methods
Samples from CLL patients and healthy donors
After informed consent, CLL cells were isolated from peripheral blood mononuclear cells (PBMCs) of 60 patients by FicollPaque TM density gradient (GE Healthcare, UK). B-CLL diagnosis was obtained according to clinical and immunophenotypic criteria. The study was approved by the Ethics Committee of the Federico II University. Blood was collected from patients before initiating chemotherapy, or not subjected to therapy for at least one year. Follow-up samples, after the second cycle (9 patients) and the fourth cycle (1 patient) of therapy, were also collected. PBMCs of age-matched healthy-donors were included as controls in real-time PCR experiment or in Chromatin Immunoprecipitation Assay (X-ChIP). For X-ChIP, PBMCs were cultured in RPMI (Sigma, MO, USA) supplemented with 10% FBS and treated with 10 lg anti-IgM (Sigma) for 24 h.
Cell lines and reagents
The human cell lines MEC1, MC3 (EBV-immortalized human B cells) (28) and Jurkat were used for in vitro experiments and cultured at 37 C with 5% CO 2 in RPMI (Sigma) supplemented with 10% FBS. HEK293T/17 cell line was cultured in DMEM (Sigma) supplemented with 10% FBS. MEC1 cells were treated with 50 lM fludarabine (Teva, UK) (29) Jurkat cells were treated 3 lM or 9 lM fludarabine. Cells treated with different excipients (10% mannitol and 0,01% sodium hydroxide) served as control (-Flu or NT).
Statistical methods
Variables are characterized using mean 6 standard deviation (SD) or median with interquartile range (25 th and 75 th percentile).
ZNF224-expression comparison analysis in CLL patient groups was based either on Student's-T-test for independent samples, or on the exact Mann-Whitney U test. One-sample t-test was used in case of normalized values. The longitudinal variation of expression level of ZNF224 after drug treatment was assessed using the Wilcoxon test. Correlation among variables was computed using the Pearson's correlation coefficient. All tests were two-sided, and a P <0.05 was deemed significant. Statistical analysis was performed using R statistical computing software (R Foundation for Statistical Computing, Vienna, Austria).
Cell lysates and western blot assays
Total cell lysates were prepared by homogenization in modified RIPA buffer as previously described (30 
Plasmid construction
The flag-ZNF224 coding sequence was amplified from the p3xFLAG-ZNF224 expression vector (5) using the following primers: XbaI-Fw:5'-GCTCTAGAGCCCATGGACTACAAAGACCATGA CG-3') and BamHI-Rw:5'-CGGGATCCCGTCACTAAGGTTTTTCT CCAACATG-3'). PCR was performed using Expand Long Template PCR System (Roche, Basilea, Switzerland). The amplified cDNA was cloned into XbaI/BamHI sites of pHIV-EGFP vector (Addgene, Cambridge, MA, USA). Two different lentiviral constructs (pHIV-ZNF224.4 and pHIV-ZNF224.8) were selected for the experiments.
Transient transfection, stable transfection and luciferase assay ZNF224 short interfering (si)RNA (sequence: 5'-ACCACTAGAAA CATACCTGTA-3'), or a scrambled oligo as control, were transiently transfected in MC3 cells using HiPerFect Reagent (Qiagen, Hilden, Germany), according to the manufacturer's recommendations. To obtain stable ZNF224-silencing, MEC1 cells were electroporated (300V/960 lF) with shRNA plasmids SH2351C3 or SH2352E7 (Open Biosystems, AL, USA) in RPMI supplemented with 10% FBS and 1,25% DMSO, using a Gene Pulser II System (Biorad, Berkeley, CA, USA). As a negative control, pools of MEC1 stably transfected with a shGFP RNA plasmid (Open Biosystems) were considered. For luciferase-reporter assay, MEC1 and Jurkat cells were transiently transfected with 300 ng of a luciferase reporter plasmid containing the ZNF224 promoter (PromZNF224-Luc) (9) using Lipofectamine Reagent (Invitrogen). After 24 h, cells were treated for further 24-48 h with 50 mM (MEC1) and 3mM (Jurkat) of fludarabine, respectively. pRL-CMV plasmid coding for the renilla luciferase served as luciferase normalization. Luciferase activity was measured using the Dual-Luciferase Reporter Assay System (Promega Corporation, WI, USA) according to manufacturer's instructions.
Lentiviral transduction of jurkat and MEC1 cells
Lentiviral particles were harvested after transfection of HEK293T/17 cells with 5 lg of packaging plasmids pD8.9 and pVSVG, and 5 lg of pHIV-ZNF224.4 or pHIV-ZNF224.8 or pHIV-EGFP using Metafectene reagent (Biontex, Munich, Germany), according to the manufacturer's recommendations. Supernatants were used to infect (two rounds) Jurkat and MEC1 clones (MEC1.C3/E7) by spin inoculation in the presence of polybrene (1:1000).
RNA isolation, reverse transcription and real-time PCR
Total RNA was extracted using TRizol (Invitrogen, Carlsbad, USA), according to the manufacturer's instructions. One microgram of total RNA was reverse-transcribed using iScript Reverse Transcription Supermix for RT-qPCR (Bio-Rad), as recommended by the manufacturer. Real-time PCR was carried out with the Master Mix SYBR Green (Bio-Rad) and specific primers for: ZNF224 (8); HPRT (Fw-5'-TGACACTGGCAAAACAATGCA-3'; Rw-5'-GGTCCTTTTCACCAGCAAGCT-3'); SDHA (Fw-5'-TGGGAA CAAGAGGGCATGTG-3'; Rw-5'-CCACCACTGCATCAAATTCATG-3'); PPIA (31); GAPDH (Fw-5'-CCATGGAGAAGGCTGGGG-3'; Rw-5'-CAAAGTTGTCATGGATGACC-3'); 18S (32); Ki67 (Fw-5'-ATCAG AAAGGGAAAGGAGAAGC-3'; Rw-5'-TCACTGTCCCTATGACTTCT GG-3'); CyclinA and ACTB (33); CyclinD3, CyclinB1 and CyclinD1 were validated QuantiTec primers (Qiagen Valencia, CA, USA). The relative quantification in gene expression was determined using the DDCT method. Through the software geNorm TM (http://medgen.ugent.be/$jvdesomp/genorm/), HPRT transcript was chosen from a set of tested candidate reference genes (HPRT, SDHA, PPIA, ACTB, G3PDH and RNA18S) in a panel of healthy donors and CLL patients. The program calculates the Mvalue for different candidate genes. The most stable reference genes are those with a value of M < 1.5. To adjust the M-value of genes which are included in the calculation of a normalization factor, we excluded the reference gene with higher M-value (Supplementary Material, Table S1 ).
Chromatin immunoprecipitation
ChIP assay was performed as previously described. 4 For each assay five different activated PBMCs were pooled. The following antibodies were used: anti-ZNF224 (G16, Santa Cruz Biotechnology), H3meK4 and H3meK27 (Millipore Corporation, MA, USA) and immunoglobulin G (IgG, Sigma). Immunoprecipitated DNA and input controls were analysed by quantitative real-time PCR using a Master Mix SYBR Green (Bio-Rad) and the following primer pairs for CCND3 promoter: CCD3P1 (Fw-5'-CATGTGCCGTTATGGTTCAC-3'; Rw-5'-AGCCTGG ACAACAAAGCAAG-3'); CCD3P2 (Fw-5'-ATGACAGTTGCCTCGGTTTC-3'; Rw-5'-CCATTTTGCTTCTCGGACTC-3'); CCD3INT1 (Fw-5'-ATTAAACCCCCTCCTCCTGA-3'; Rw-5'-CCACATGAAGCACATTCCAC-3'); CCD3INT2 (Fw-5'-TGAGGGTAGGGGTTGATTTG-3'; Rw-5'-AGTCCACTCGTCATGGGTTC-3'). Fold enrichment was calculated as previously described (9) .
Cell cycle and apoptosis assay
Cell death was assayed by phosphatidylserine externalization, investigated by annexin V (FITC or APC-conjugated) staining and analysis of the DNA content by propidium iodide (PI) incorporation, performed as previously described (34) . For cell cycle analysis MEC1 clones were harvested, fixed in cold 70% ethanol, added drop-wise to the pellet while vortexing to minimize clumping. After 2 h at À20 C, cells were washed, RNase treated and stained with PI. All samples were analysed by a FACScan (Becton Dickinson, BD), flow cytometer and/or a C6
BDAccuri flow cytometer (BD). For PI assays, clumps and doublets were excluded from the analysis and DNA content of the nuclei was registered on a logarithmic or linear scale for apoptosis and cell cycle, respectively.
